Literature DB >> 11278656

Particle formation by a conserved domain of the herpes simplex virus protein VP22 facilitating protein and nucleic acid delivery.

N Normand1, H van Leeuwen, P O'Hare.   

Abstract

VP22, a structural protein of herpes simplex virus, exhibits unusual trafficking properties which we proposed might be exploited in gene and protein delivery applications. To pursue the use of the protein itself for cargo delivery into cells, we developed an expression system for the C-terminal half of VP22, residues 159-301 (VP22.C1), and purified the protein in high yields. Addition of short oligonucleotides (ODNs) induced the assembly of novel particles, which were regular spheres with a size range of 0.3 to 1.0 microm in diameter, incorporating both protein and ODN. Following the particles in living cells using fluorescently tagged ODNs, we show that they enter efficiently within 2-4 h, and reside stably in the cell cytoplasm for up to several days. Remarkably, however, light activation induced particle disruption and release of the protein and ODN to the nucleus and cytoplasm within seconds, a process that we have captured by time lapse microscopy. In addition to delivering antisense ODNs, ribozymes, and RNA/DNA hybrids, the VP22.C1 protein could also be modified to include peptides or proteins. These particles have the potential for delivery of a wide range of therapeutic agents in gene therapy and vaccine development.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11278656     DOI: 10.1074/jbc.M010294200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  15 in total

1.  Characterization of Marek's disease virus serotype 1 (MDV-1) deletion mutants that lack UL46 to UL49 genes: MDV-1 UL49, encoding VP22, is indispensable for virus growth.

Authors:  Fabien Dorange; B Karsten Tischer; Jean-François Vautherot; Nikolaus Osterrieder
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

2.  Might a vanguard of mRNAs prepare cells for the arrival of herpes simplex virus?

Authors:  Thomas Shenk
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-25       Impact factor: 11.205

Review 3.  Peptides in cancer nanomedicine: drug carriers, targeting ligands and protease substrates.

Authors:  Xiao-Xiang Zhang; Henry S Eden; Xiaoyuan Chen
Journal:  J Control Release       Date:  2011-10-26       Impact factor: 9.776

4.  Characterization of VP22 in herpes simplex virus-infected cells.

Authors:  G Mouzakitis; John McLauchlan; Cristina Barreca; Lisa Kueltzo; P O'Hare
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

Review 5.  The taming of the cell penetrating domain of the HIV Tat: myths and realities.

Authors:  Ashok Chauhan; Akshay Tikoo; Arvinder K Kapur; Mahavir Singh
Journal:  J Control Release       Date:  2006-11-17       Impact factor: 9.776

6.  Evidence of a role for nonmuscle myosin II in herpes simplex virus type 1 egress.

Authors:  Hans van Leeuwen; Gill Elliott; Peter O'Hare
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

7.  VP22 enhances the expression of glucocerebrosidase in human Gaucher II fibroblast cells mediated by lentiviral vectors.

Authors:  Gui-shan Jin; Gui-dong Zhu; Zhi-gang Zhao; Fu-sheng Liu
Journal:  Clin Exp Med       Date:  2011-08-28       Impact factor: 3.984

8.  Protein transduction domains fused to virus receptors improve cellular virus uptake and enhance oncolysis by tumor-specific replicating vectors.

Authors:  Florian Kühnel; Bernd Schulte; Thomas Wirth; Norman Woller; Sonja Schäfers; Lars Zender; Michael Manns; Stefan Kubicka
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

9.  The varicella-zoster virus (VZV) ORF9 protein interacts with the IE62 major VZV transactivator.

Authors:  Cristian Cilloniz; Wallen Jackson; Charles Grose; Donna Czechowski; John Hay; William T Ruyechan
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

10.  Purification of full-length VP22 from cells infected with HSV-1: A two-pronged approach for the solubilization and purification of viral proteins for use in biochemical studies.

Authors:  Ebony J Dewberry; Eric Dunkerley; Carol Duffy
Journal:  J Virol Methods       Date:  2012-04-28       Impact factor: 2.014

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.